小剂量环孢素A逆转肾癌细胞多药耐药及其机制探讨  

Reversal of multidrug resistance in renal cell carcinoma RCC 925 cell line with cyclosporin A in lower dose

作　　者：余玉明[1] 苏泽轩[2] 

机构地区：[1]中国人民解放军第157医院泌尿外科,510510 [2]暨南大学医学院第一附属医院泌尿外科,510632

出　　处：《广东医学》2000年第12期1010-1011,共2页Guangdong Medical Journal

摘　　要：目的　探讨小剂量环孢素A对肾癌细胞多药耐药的逆转及其机制。方法　通过体外实验用MTT法测定逆转前后肾癌细胞存活率 ,检测逆转前后P糖蛋白表达情况。结果　小剂量环孢素A(≤ 1mg/L)可以逆转RCC 92 5肾癌细胞对阿霉素和长春新碱的耐药 ,还可诱导RCC 92 5肾癌细胞表达P糖蛋白水平增高。结论　人体最大耐受剂量之内的环孢素A可以逆转RCC 92 5肾癌细胞的多药耐药 ,其机制与P糖蛋白表达有关。Objective To study the mechanisms of multidrug resistance in renal cell carcinoma with low dose of (Cyclospori A, CsA) of lower dose. Methods Low dose of CsA was used to reverse the resistance to Adriamycin(ADM) and Vincristine(VCR) on renal cell carcinoma RCC 925 cell line in vitro with MTT technique. The expression of P glycoprotein(Pgp) was analyzed by flow cytometry before and after the reversal of multidrug resistance in RCC 925 cell carcinoma. Results Low dose of CsA (≤1 mg/L) could reverse the resistance to ADM and VCR in RCC 925 cell line. CsA could increase the expression of Pgp in renal cell carcinoma RCC 925 cell line. Conclusion CsA within human tolerance dose can reverse the resistance to ADM and VCR in RCC 925 cell line, which is related to Pgp expression.

关 键 词：环孢素A 肾癌 多药耐药性 P糖蛋白 

分 类 号：R737.11[医药卫生—肿瘤] R979.5[医药卫生—临床医学]